BioNTech Founders Launch New mRNA Company, Depart Current Roles

The co-founders of BioNTech, renowned for their development of the Covid-19 vaccine, are set to leave the company to establish a new venture focused on messenger RNA (mRNA) technology. Ugur Sahin and Özlem Türeci announced their decision on Tuesday, revealing plans to transition to their yet-to-be-named enterprise by the end of 2023.

This new company will concentrate on researching and developing next-generation mRNA medicines, expanding the potential applications of this innovative technology beyond Covid-19. BioNTech will support the initiative by transferring certain rights to its mRNA technology and acquiring a minority stake in the new firm.

The decision by Sahin and Türeci marks a significant shift in their careers, as they have played pivotal roles in BioNTech’s success. The couple’s groundbreaking work in mRNA technology has been instrumental in the rapid development of effective vaccines during the pandemic, positioning BioNTech as a leader in the biotech industry.

As they embark on this new chapter, the founders expressed their commitment to advancing mRNA science. In a statement, Sahin noted, “Our new venture will aim to harness the full potential of mRNA technology to address a range of diseases.” Türeci added, “We are excited to explore new horizons in this field and to contribute further to the advancement of medicine.”

BioNTech, based in Germany, plans to maintain a strategic relationship with the new company. By retaining a stake in the venture, BioNTech aims to continue its involvement in the evolving landscape of mRNA applications. The collaboration is expected to leverage BioNTech’s existing research capabilities while allowing Sahin and Türeci the freedom to explore innovative ideas.

The launch of this new mRNA-focused company signals a broader trend within the biotech sector, where mRNA technology is being increasingly recognized for its potential beyond vaccines. Researchers and companies are investigating its applications in areas such as cancer treatment and rare genetic disorders.

As this transition unfolds, the biotech community will be watching closely. The founders’ move could inspire further developments in mRNA research and development, with potential implications for global health advancements. The excitement surrounding this new venture reflects the ongoing evolution of the biotech industry, particularly in the wake of the pandemic.

In conclusion, Sahin and Türeci’s departure from BioNTech represents not only a significant personal shift but also a potential leap forward for mRNA technology. Their new company could pave the way for innovative therapies, continuing their legacy of scientific advancement. As they prepare to take this bold step, the future of mRNA medicine remains bright and full of possibilities.